Insilico Medicine has nominated ISM1354, an orally available small molecule targeting the glucose-dependent insulinotropic polypeptide receptor, as a preclinical candidate for obesity, type 2 diabetes and related cardiometabolic disease. Reported preclinical data include 75-104% oral bioavailability across four species, at least 18-fold greater plasma exposure than a clinical-stage comparator at equivalent dose, and a 45-fold safety margin in non-GLP monkey toxicology. The compound was generated through AI-driven multi-objective molecular design and now moves toward GLP toxicology studies.
Key Points
- AI-designed oral GIPR small molecule nominated as preclinical candidate
- Oral bioavailability 75-104% across mice, rats, dogs, monkeys
- Weaker OATP1B1 inhibition and lower hepatocyte toxicity than benchmark
Longevity Analysis
Cardiometabolic disease remains the dominant driver of age-related mortality, and oral incretin-pathway agents could extend metabolic intervention to populations unwilling or unable to use injectables. The liver safety profile reported here is as consequential as the potency data, since sustained metabolic therapy depends on hepatic clearance pathways tolerating years of exposure rather than months. Receptor-level manipulation of appetite and glucose handling works through signalling the body already uses to regulate energy availability; the question that matters over decades is whether that signalling can be modulated without burdening the organs responsible for processing the compound itself.
Original published by LT Wire.